Treatment of 22Q11.2 deletion syndrome with cannabidiol

12186,282

17/957932

September 30, 2022

The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q 11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q 11.2 deletion syndrome are treated in the subject.

Harmony Biosciences Management, Inc. (Plymouth Meeting, PA, US)

HARMONY BIOSCIENCES MANAGEMENT, INC. (Plymouth Meeting, PA, US)

1. A method of treating one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome in a subject, the method comprising: administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.2 deletion syndrome are treated in the subject.

2. The method of claim 1 , wherein the administration of CBD is effective for the treatment of general anxiety in the subject.

3. The method of claim 1 , wherein the CBD is (−)-CBD.

4. The method of claim 1 , wherein the effective amount of CBD is between about 50 mg and about 1000 mg total daily.

5. The method of claim 1 , wherein the CBD is formulated as a gel.

6. The method of claim 1 , wherein the CBD is administered in a single daily dose.

7. The method of claim 1 , wherein the CBD is administered in two daily doses.

8. The method of claim 1 , wherein the CBD is formulated as a permeation-enhanced gel.

9. The method of claim 1 , wherein the CBD is transdermally administered on the subject's arm.

10. The method of claim 1 , wherein the CBD is a synthetic CBD.

11. The method of claim 1 , wherein the CBD is botanically derived.

12. The method of claim 1 , wherein the CBD is purified.

13. The method of claim 1 , wherein administering comprises transdermally administering.

14. The method of claim 13 , wherein transdermally administering an effective amount of cannabidiol (CBD) reduces an intensity of at least one adverse event relative to orally administering CBD.

15. The method of claim 14 , wherein the at least one adverse event is selected from the group consisting of somnolence, psychoactive effects, liver function, and GI related adverse events.

16. The method of claim 1 , wherein the effective amount of CBD is about 125 mg total daily.

17. The method of claim 1 , wherein the effective amount of CBD is about 250 mg total daily.

18. The method of claim 1 , wherein the effective amount of CBD is about 500 mg total daily.

19. The method of claim 1 , wherein the effective amount of CBD is about 750 mg total daily.

20. The method of claim 1 , wherein the effective amount of CBD is about 1000 mg total daily.

7423026 September 2008 Jarvinen et al.
8293786 October 2012 Stinchcomb et al.
8435556 May 2013 Stinchcomb et al.
8449908 May 2013 Stinchcomb et al.
9375417 June 2016 Smith et al.
9447019 September 2016 Mechoulam et al.
9533942 January 2017 Stinchcomb et al.
9675656 June 2017 Crowley
9730911 August 2017 Verzura et al.
9782360 October 2017 Mechoulam et al.
9943491 April 2018 De Vries et al.
10213390 February 2019 Bonn-Miller et al.
10314792 June 2019 Sebree et al.
10471022 November 2019 Bonn-Miller et al.
10555928 February 2020 Blackmon et al.
10568848 February 2020 Sebree et al.
10716766 July 2020 Aung-Din
10758497 September 2020 Bonn-Miller et al.
11458109 October 2022 Sebree
2008/0139472 June 2008 Lauterborn et al.
2010/0273895 October 2010 Stinchcomb et al.
2011/0052694 March 2011 Stinchcomb et al.
2015/0342902 December 2015 Vangara et al.
2015/0343071 December 2015 Vangara et al.
2016/0000843 January 2016 Lowe et al.
2016/0022627 January 2016 Smith
2016/0256410 September 2016 Aung-Din
2016/0256411 September 2016 Aung-Din
2016/0271252 September 2016 Vangara et al.
2016/0338974 November 2016 Aung-Din
2017/0224634 August 2017 Vangara et al.
2017/0231923 August 2017 Guy et al.
2017/0274030 September 2017 Crowley
2017/0348276 December 2017 Bryson et al.
2017/0360745 December 2017 Blackmon et al.
2018/0140560 May 2018 De Vries et al.
2019/0117619 April 2019 Guy et al.
2020/0188324 June 2020 Sebree et al.
2020/0360299 November 2020 Bonn-Miller et al.
2021/0196669 July 2021 Bar-Lev Schleider et al.
2021/0369643 December 2021 Sebree et al.
2021/0401769 December 2021 Griesser et al.
2022/0096396 March 2022 Sebree et al.
2023/0024756 January 2023 Sebree et al.
2023/0059709 February 2023 Palumbo et al.
2023/0364028 November 2023 Sebree et al.
2023/0414533 December 2023 Bonn-Miller et al.
2024/0122873 April 2024 Griesser et al.
2018101357 October 2018
107126411 September 2017
2549278 October 2017
2006133941 December 2006
WO-2010127033 November 2010
WO-2016109624 July 2016
2016141056 September 2016
WO-2017068349 April 2017
WO-2017149387 September 2017
WO-2017151980 September 2017
WO-2017158539 September 2017
WO-2017178807 October 2017
WO-2017178810 October 2017
WO-2017182950 October 2017
2018011808 January 2018
WO-2018002637 January 2018
WO-2018109471 June 2018
2019034985 February 2019
2019089583 May 2019
2022017942 January 2022

U.S. Appl. No. 16/737,326. cited by applicant
U.S. Appl. No. 17/895,008. cited by applicant
U.S. Appl. No. 17/941,739. cited by applicant
U.S. Appl. No. 17/942,068. cited by applicant
Busquets-Garcia, Arnau, et al., Targeting the endocannabinoid system in the treatment of fragile X syndrome, Nature Medicine (Mar. 2013). cited by applicant
International Search Report and Written Opinion of corresponding PCT/IB2019/060735, mailed Mar. 3, 2020, 12 pages. cited by applicant
Banks S, O'Neill C, Sebree T. Pharmacokinetic Evaluation of Subcutaneously Administered ZYN001 in Male Sprague-Dawley Rats. PAINWeek. Sep. 8-12, 2015. cited by applicant
Bergmaschi et al., Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naiver Social Phobia Patients, Neuropsychopharmacology (2011) 36, 1219-1226. cited by applicant
Blessing et al., Cannibidiol as a Potential Treatment for Anxiety Disorders, Neurotherapeutics, Oct. 2015, 12(4): 825-836. cited by applicant
Bonn-Miller M, Banks SL, Sebree T. Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. Cannabis and Cannabinoid Research 2017;2:1, 5-7. cited by applicant
Bonn-Miller M, Gutterman D. A Permeation-Enhanced Synthetic Cannabidiol (CBD) Transdermal Gel for the Treatment of PTSD. Military Health System Research Symposium. Orlando, FL. Aug. 15-18, 2016. cited by applicant
Bonn-Miller M, Sebree T, O'Neill C, Messenheimer J. Neuropsychological Effects of ZYN002 (Synthetic Cannabidiol) Transdermal Gel in Healthy Subjects and Patients with Epilepsy: Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies. American Epilepsy Society Annual Meeting. Houston, TX. Dec. 2-6, 2016. cited by applicant
Fusar-Poli, et al., “Modulation of Effective Connectivity During Emotional Processing by A9- tetrahydrocannabinol and Cannabidiol,” International Journal of Neuropsychopharmacology (2010) 13, 421-432. cited by applicant
Gauvin D, O'Neill C, Patterson DR. Respiratory Evaluation of Subcutaneously Administered ZYN001 in Male Sprague-Dawley Rats. PAINWeek. Sep. 8-12, 2015. cited by applicant
Jung KM, Sepers M, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 2012;3:1080. cited by applicant
Kidd, et al., Cannabinoids in the Treatment of Autism Spectrum Disorder: Demanding Data Before Using Fad Therapies, Pediatric Neurology, 88 (2018) 10-11. cited by applicant
Lozano, et al., “Advances in the Understanding of Gabaeric Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder,” Curr Pharm Des Author manuscript, (2015); 21 (34): 4972-4979. cited by applicant
Merrick J, Lane B, Sebree T, Yaksh T, O'Neill C, Banks SL. Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis and Cannabinoid Research 2016;1:1, 102-112, DOI: 10.1089/can.2015.0004. cited by applicant
Novagant Corp. Announces Breakthrough in Cannabidiol (CBD) Transdermal Patch for Localized Delivery, Oct. 29, 2014. cited by applicant
O'Brien T MD, FRACP; Berkovic, S, MD, FRACP; French, J, MD, et al. Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy in Adults. 2017 American Epilepsy Society Annual Meeting, Washington, DC. Dec. 1-5, 2017. cited by applicant
Paudel KS, Hammell DC, et al. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Development and Industrial Pharmacy 2010;36(9):1088-1097. cited by applicant
Qin M, Zeidler Z, et al. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome. Behav Brain Res Sep. 15, 2015;291:164-71. cited by applicant
Salgado, et al., Autism Spectrum Disorder and Cannabidiol: Have We Seen This Movie Before?, Global Pediatric Health, vol. 5:1-5 (2018). cited by applicant
Sativex Product Monograph, Buccal Spray, Mar. 30, 2012 (55 pages). cited by applicant
Sebree T, O'Neill C, Messenheimer J, Gutterman D. Safety and Tolerability of ZYN002 (Synthetic Cannabidiol) Transdermal Permeation-Enhanced Gel in Healthy Subjects and Epilepsy Patients: Three Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies. American Epilepsy Society Annual Meeting. Houston, TX. Dec. 2-6, 2016. cited by applicant
Wei, et al., Enhancement of Anandamide-Mediated Endocannabinoid Signally Corrects Autism-Related Social Impairment, Cannabis and Cannabinoid Research, vol. 1.1 (2016). cited by applicant
Wheeler, et al., “Anxiety, Attention Problems, Hyperactivity, and the Aberrant Behavior Checklist in Fragile X Syndrome,” American Journal of Medical Genetics, (2013) 141-155. cited by applicant
Winton-Brown, et al., “Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMR1 Study,” Neuropsychopharmacology (2011) 36, 1340-1348. cited by applicant
Hadland, S., et al., “Medical Marijuana: Review of the Science and Implications for Developmental Behavioral Pediatric Practice,” J Dev Behav Pediatr. 2015 ; 36(2): 115-123. cited by applicant
Aran, A., et al., “Cannabidiol Based Medical Cannabis in Children with Autism—a Retrospective Feasibility Study (P3.318),” Neurology, 90:15 Supplement, (2018). cited by applicant
Pavlovic, Zoran M., “Cannabinoids in Autism and Fragile X Syndrome: Value-Based Treatment Revolution Ahead?,” Global Journal of Intellectual & Developmental Disabilities, 3(1) 1-4 (Sep. 2017). cited by applicant
Khalil, Rami Bou, “Would some cannabinoids ameliorate symptoms of autism?”, European Child & Adolescent Psychiatry, 21(4):237-238, XP035037636, ISSN: 1435-165X, DOI: 10.1007/S00787-012-0255-Z (2017). cited by applicant
Anonymous: History of Changes for Study: NCT02956226, “Cannabinoids for Behavioral Problems in Children with ASD (CBA)”, XP055718101, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history/NCT02956226?V_4=View#StudyPageTop [retrieved on Jul. 27, 2020] (2017). cited by applicant
Hammell, D.C., et al., “Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis”, Eur. J. Pain, vol. 20(6):936-948. doi:10.1002/ejp.818 (Jul. 2016). cited by applicant
Heussler, Helen et al., “A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome”, Journal of Neurodevelopmental Disorders, vol. 11, No. 1, pp. 1-9, XP055828347 (2019). cited by applicant
Belmonte, Matthew K., et al., “Fragile X syndrome and autism at hte intersection of genetic and neural networks”, Nature Neuroscience, vol. 9(10):1221-1225 (2006). cited by applicant
Hagerman, Randi, et al., “Fragile X Syndrome and Targeted Treatment Trials”, National Institutes of Health Public Access Manuscript, published as Results Probl Cell Differ., vol. 54:297-335. doi:10.1007/978-3-642-21649-7_17 (2012). cited by applicant
Kaufmann, Walter E., et al., “Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment”, HHS Public Access Manuscript, published as Pediatrics, vol. 139(Suppl 3):S194-S206. doi:10.1542/peds.2016-1159F (2017). cited by applicant
Pisante, S., et al., “Cannabidiol: State of the Art and New Challenges for Therapeutic Applications”, Pharmacology and Therapeutics, vol. 175, pp. 133-150 (2017). cited by applicant
Mechoulam, Raphael, et al., “Cannabidiol: An Overview of Some Pharmacological Aspects”, The Journal of Clinical Pharmacology, vol. 42, Issue 51, pp. 11S-19S (2002). cited by applicant
Mechoulam, Raphael, et al., “Cannabidiol—Recent Advances”, Chemistry & Biodiversity; vol. 4, pp. 1678-1692 (2007). cited by applicant
Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures (Aug. 7, 2017). cited by applicant
Hagerman, Randi J., et al., “Fragile X-Associated Neuropsychiatric Disorders (FXAND),” Frontiers in Psychiatry, vol. 9. Article 564, pp. 1-9 (2018). cited by applicant
Crawford, Dana C., et al., “FMR1 and the Fragile X Syndrome: Human Genome Epidemiology Review,” Genet. Med., Author manuscript, HHS Public Access, vol. 3(5):359-371 (2001). cited by applicant
Godler, David Eugeny, et al., “Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio,” Human Molecular Genetics, vol. 9(18):1618-1632 (2010). cited by applicant
SDCAadmin, “The Difference Between Moderate to Severe Autism,” Sarah Dooley Center for Autism, pp. 1-6 (2019). cited by applicant
Aran, Adi, et al., “Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study,” Journal of Autism and Developmental Disorders, vol. 49:1284-1288 (2019). cited by applicant
Hagerman, Randi J., et al., “High Functioning Fragile X Males: Demonstration of an Unmethylated Fully Expanded FMR-1 Mutation Associated with Protein Expression,” American Journal of Medical Genetics, vol. 51:298-308 (1994). cited by applicant
International Preliminary Report on Patentability for corresponding PCT/US2022/078449 dated Apr. 24, 2024, 9 pages. cited by applicant
Ali, Shayma et al., “Efficacy of cannabinoids in paediatric epilepsy”, Developmental Medicine & Child Neurology, vol. 61:13-18 (2019). cited by applicant
Kuchenbuch, Mathieu, et al., “Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy,” Epilepsia Open, vol. 5:496-500 (2020). cited by applicant
SynGAP Research Fund, Webinar, CBD, Seizures & SynGAP: Parents Experience (2019). cited by applicant
Vlaskamp, Danique R.M., et al., “SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy,” Neurology, vol. 92(2):e96-e107 (2019). cited by applicant
“Lacking guidance from doctors, parents lead the charge in treating children with CBD,” Peninsula Press (2018). cited by applicant
Salcedo-Arellano, Maria Jimena, et al., “Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments”, Neurotherapeutics, Springer International Publishing, Cham, vol. 18, No. 1, pp. 265-283 (2020). cited by applicant
International Search Report and Written Opinion for corresponding PCT/US2022/078449 mailed Feb. 2, 2023, 13 pages. cited by applicant
Hagerman, Paul J., Ph.D., M.D et al., Fragile X Syndrome: Diagnosis, Treatment, and Research, The Johns Hopkins University Press, pp. 210, 213, 471 and 472, 3rd Edition (2002). cited by applicant
Liu, X. Shawn, et al., Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FRM1 Gene, Cell Press, vol. 172:979-992 (2018). cited by applicant
Payan Gomez, Cesar, et al., “Variable Expressivity in Fragile X Syndrome: Towards the Identification of Molecular Characteristics That Modify the Phenotype”, The Application of Clinical Genetics, DovePress, vol. 14:305-312 (2021). cited by applicant
Clinical Leader: Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome, retrieved from the internet at URL:, retrieved on Aug. 31, 2023 (2017). cited by applicant
Buckner, Julia D., et al., “Cannabis-related impairment and social anxiety: the roles of gender and cannabis use motives”, Addictive Behaviors, vol. 37(11):1294-1297 (2012). cited by applicant
Fung, Wai Lun Alan, et al., “Elevated Prevalence of Generalized Anxiety Disorder in Adults 22q11.2 Deletion Syndrome”, American Journal of Psychiatry, vol. 167(8):998, XP009553437 (2010). cited by applicant
Siegel, Steven, et al., Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome (FXS), ACNP 57th Annual Meeting: Poster Session III, Neuropsychopharmacology, vol. 43, Suppl. 1, pp. S399-S400, XP093109132 (2018). cited by applicant
International Search Report and Written Opinion for corresponding PCT/IB2021/054543 dated Dec. 8, 2021, 10 pages. cited by applicant
International Preliminary Report on Patentability for corresponding PCT/IB2021/054543 dated Nov. 17, 2022, 7 pages. cited by applicant
Maneeton, Narong, et al., “Risperidone for children and adolescents with autism spectrum disorder: a systematic review”, Neuropsychiatric Disease and Treatment, vol. 14:1811-1820 (2018). cited by applicant
National Library of Medicine; Natonal Center for Biotechnology Information; PubChem; Compound Summary—Cannabidiol; 67 pages (2014). cited by applicant
Heussler, H. et al., “Transdermal cannabidiol (CBD) Gel for the treatment of fragile X syndrome (FXS)”, 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL. 2018, Poster P5-092, . cited by applicant

edspgr.12186282